Log In
Print this Print this

odanacatib (formerly MK-0822)

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionCathepsin K inhibitor
Molecular Target Cathepsin K (CTSK)
Mechanism of ActionCathepsin K inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationOsteoporosis
Indication DetailsTreat osteoporosis
Regulatory Designation
Partner Quest Diagnostics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today